


Compare chosen products from different angles with the Analysis table

This guide explains how to create a table that evaluates products of interest you choose - either competitor products or potential candidates for your portfolio - and compare them from different angles.


Analysis table in the Product Selector Tool helps you evaluate profitability*, API availability, expected loss of exclusivity (LOE) dates and other relevant data for products of interest in a customizable, downloadable table.

Example: Compare API availability and expected LOE dates in the US and the UK for protein kinase inhibitors such as *acalabrutinib*, *afatinib dimaleate* and *ponatinib hydrochloride*.

1. Login to **Cortellis Generics Intelligence**.
2. Go to **Product Selector Tool** and scroll down.



3. Enter the API names of interest, select from the suggestions and click '**Search**'.



4. Analysis table displays API availability, expected LOE dates and additional data for the products of interest.
Sorting options at the top allow you to rank results by sales trend, for example.

Analysis Compare Pack Prices

Customize Columns Export Country/Territory ? USA Rows per page: 10 1-3 of 3


API NAME ↑	SALES TREND ↓	API AVAILABILITY ⓘ	CONSTRAINT DATE FORECAST ⓘ	FIRST US APPROVAL DATE (ANDA/ABLA)	ORANGE BOOK EXCLUSIVITIES	FIRST EUROPEAN APPROVAL
<input type="checkbox"/> acalabrutinib	↑ 53.8%	Limited Sources	24-Nov-2026, USA 05-Nov-2035, UK	18-Jan-2023	31-Oct-2024, ODE-175 21-Nov-2026, ODE-274	05-Nov-2020, EU 05-Nov-2020, EEC ***
<input type="checkbox"/> ponatinib hydrochloride	↑ 0.7%	Limited Sources	22-Dec-2026, USA 02-Jul-2028, UK	13-Mar-2023	18-Dec-2023, I-849	01-Jul-2013, EU 01-Jul-2013, EEC ***
<input type="checkbox"/> afatinib dimaleate	↓ -11%	Regulated Markets	13-Jan-2026, USA 11-Jun-2027, UK	02-Nov-2020	15-Apr-2023, ODE-115 15-Oct-2023, PED ***	25-Sep-2013, EEC 25-Sep-2013, EU ***

Click 'i' to learn more about proprietary terminology.

As of July 2023:

- *Afatinib dimaleate* was expected to have generic competition sooner than the other 2 products: Jan 2026 in the US and Jun 2027 in the UK.
- Some API manufacturers were producing commercial quantities of *acalabrutinib* for more regulated countries, but the market is not saturated yet. The other two products are only manufactured by a handful companies for the same territories.

- Click '**Customize columns**' to hide, show and reorder columns in your Analysis table.



* Users with access to Cortellis Generics Global and Premium can also display and export sales volume, sales trends, indications, highest phase reached, brand names, number of marketers and names. In addition, users with access to Cortellis Generics Premium are able to display and export API consumption and trends.

To find out what's included in your subscription, contact your Clarivate account manager or **LS Product Support**.